First known was to use Prussian blue, which is a solid ion exchange material, which absorbs thallium. Up to 20 g per day of Prussian blue is fed by mouth to the person, and it passes through their digestive system and comes out in the stool. Hemodialysis and hemoperfusion are also used to remove thallium from the blood stream. At later stage of the treatment additional potassium is used to mobilize thallium from the tissue. Notable cases
There are numerous recorded cases of fatal thallium poisoning. Because of its use for murder, thallium has gained the nicknames "The Poisoners Poison" and "Inheritance Powder" (alongside arsenic). Australias "Thallium Craze"
In Australia, in the early 1950s, there was a notable spate of cases of murder or attempted murder by thallium poisoning. At this time, due to the chronic rat infestation problems in overcrowded inner-city neighbourhoods (notably in Sydney), and thalliums effectiveness as a rat poison, it was still readily available over the counter in New South Wales, where thallium sulphate was marketed as a commercial rat bait, under the brand Thall-rat . In September 1952 Yvonne Gladys Fletcher, a housewife and mother of two from the inner Sydney suburb of Newtown, was charged and tried for the murders of both her first husband, Desmond Butler (who died in 1948), and her abusive second husband, Bertrand "Bluey" Fletcher, a rat-bait layer, from whom she had obtained the thallium poison that she used to kill him earlier that year.
Sonidegib (INN), sold under the brand name Odomzo, is a medication used to treat cancer.Sonidegib is Hedgehog signaling pathway inhibitor (via smoothened antagonism). Approvals and indications
It was approved for medical use in the United States and in the European Union in 2015It is indicated for the treatment of adults with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Pharmacology
Sonidegib is administered by mouth. Common side effects include muscle spasms, hair loss, fatigue, abdominal pain, nausea, headache, and weight loss.Sonidegib binds to and inhibits smoothened to inhibit activation of the Hedgehog pathway. Sonidegib is primarily metabolized by CYP3A and is eliminated hepatically. Development
It has been investigated as a potential treatment for:

Pancreatic cancer
Breast cancer
Basal cell carcinoma of the skin
Small cell lung cancer
Medulloblastoma
Advanced solid tumors (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme)
Acute leukemia and chronic myeloid leukemia
Myelofibrosis and essential thrombocythaemiaIt has demonstrated significant efficacy against melanoma in vitro and in vivo. It also demonstrated efficacy in a mouse model of pancreatic cancer. References
External links
"Sonidegib". Drug Information Portal. U.S. National Library of Medicine. "Sonidegib phosphate". Drug Information Portal. U.S. National Library of Medicine.